Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Stephanie Senft

Physician Assistant Palmyra, PA Physician Assistant

NPI 1861984072 CMS profile 10897862

1400 S Forge Rd, Palmyra, PA 17078

Open in the dashboard

General payments

$9,638

581 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephanie Senft of Palmyra, PA is reported in the CMS Open Payments database as having received $9,638 across 581 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,141 125
2024 General $1,461 89
2023 General $1,965 120
2022 General $1,883 128
2021 General $2,189 119

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephanie Senft
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Stephanie Senft were reported at $2,141. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Stephanie Senft Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,189 $132 $37–$438 $132
2022 $1,883 $155 $48–$522 $149
2023 $1,965 $167 $52–$557 $160
2024 $1,461 $178 $55–$600 $164
2025 $2,141 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,879 105 payments
  2. Novo Nordisk Inc $1,072 71 payments
  3. AstraZeneca Pharmaceuticals LP $864 45 payments
  4. GlaxoSmithKline, LLC. $819 78 payments
  5. Lilly USA, LLC $499 30 payments
  6. Amgen Inc. $425 29 payments
  7. Pfizer Inc. $419 32 payments
  8. Otsuka America Pharmaceutical, Inc. $317 19 payments
  9. Sanofi-Aventis U.S. LLC $282 14 payments
  10. Teva Pharmaceuticals USA, Inc. $271 15 payments
  11. Other $2,792 143 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,626 580 payments
  2. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. Ozempic $850 55 payments
  2. RYBELSUS $775 50 payments
  3. TRELEGY ELLIPTA $595 61 payments
  4. UBRELVY $587 28 payments
  5. VRAYLAR $560 34 payments
  6. QULIPTA $547 34 payments
  7. FARXIGA $525 22 payments
  8. BREZTRI $453 16 payments
  9. REXULTI $317 19 payments
  10. EVENITY $279 19 payments
  11. Other $7,878 474 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 92 drugs

Part D claims

3,823

Median for Physician Assistant: 241

Drug cost

$315,893

Median for Physician Assistant: $4,110

Branded share of claims

19.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 84 $87,993
Ozempic Semaglutide Brand 45 $55,460
Eliquis Apixaban Brand 42 $37,479
Xarelto Rivaroxaban Brand 19 $20,405
Farxiga Dapagliflozin Propanediol Brand 14 $16,624
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 16 $15,393
Myrbetriq Mirabegron Brand 18 $13,755
Linzess Linaclotide Brand 14 $10,894
Breo Ellipta Fluticasone/Vilanterol Brand 17 $9,585
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 44 $4,047

The 10 drugs with the highest cost, of 92 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$21,009

Of which drugs: $3,197

Medicare patients

164

Average age 73

Services billed

582

132 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 48%
Osteoporosis 30%
Diabetes 25%
Chronic kidney disease 22%
Depression 19%
Ischemic heart disease 15%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 39 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $180
$180 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $113
$113 16 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $79
$79 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $62
$62 14 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $59
$59 42 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 39 with Patron

Records

581 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record